PTI Australia

Proteomics International is an Australian medical technology company specializing in the industrial-scale study of the structure and function of proteins, known as proteomics. The company focuses on the development of predictive diagnostic tests and bio-analytical services using its proprietary Promarker technology platform. Its flagship product, PromarkerD, is a world-first predictive test for diabetic kidney disease that can identify the risk of kidney decline up to four years before clinical symptoms appear. Beyond kidney disease, the company maintains a robust pipeline of diagnostic tests for endometriosis, asthma, and various cancers, aiming to improve patient outcomes through early detection and personalized medicine.